Department of Pathology, University of Southern California Keck School of Medicine, 2011 Zonal Avenue, HMR 308, Los Angeles, CA 90033, USA.
Cancer Metastasis Rev. 2009 Dec;28(3-4):317-26. doi: 10.1007/s10555-009-9196-5.
Carcinoma of the urinary bladder involves alterations in multiple cellular pathways that dictate the pathology of the disease and clinical outcome of the patient. This includes alterations in regulation of the cell cycle, apoptotic mechanisms, signal transduction and tumor angiogenesis. Interrogation of alterations in multiple molecules associated with these pathways is leading to the development of biomarker panels that are capable of predicting an individual patient's outcome or response to specific treatments. With respect to gene expression profiling, two broad approaches may be identified: a global approach and a pathway-specific approach. The global approach involves a high-throughput effort to profile the entire genome, while the pathway-specific approach quantifies select genes across several pathways. While the former has a high potential for discovery of novel signatures, the latter is important in generating reproducible and concise panels that have the potential for rapid clinical implementation. A combination of both these approaches is needed for the identification and validation of robust marker panels of potential clinical importance in bladder cancer.
膀胱癌涉及多个细胞通路的改变,这些改变决定了疾病的病理学和患者的临床结局。这包括细胞周期调控、细胞凋亡机制、信号转导和肿瘤血管生成的改变。对与这些通路相关的多种分子的改变进行检测,正在导致能够预测个体患者的结局或对特定治疗反应的生物标志物组合的发展。就基因表达谱分析而言,可以确定两种广泛的方法:一种是全局方法,另一种是通路特异性方法。全局方法涉及对整个基因组进行高通量分析,而通路特异性方法则对几个通路中的选定基因进行定量分析。虽然前者具有发现新特征的高潜力,但后者在生成具有快速临床应用潜力的可重复和简洁的组合方面很重要。需要结合这两种方法来鉴定和验证膀胱癌中具有潜在临床重要性的稳健标志物组合。